Decipher Labs Ltd
NSE: BSE: 524752
₹7.42
(4.07%)
Fri, 29 May 2026, 03:06 pm
Market Cap0
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KDecipher Labs Analysis
dividend
- Unable to evaluate Decipher Labs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Decipher Labs's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Decipher Labs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Decipher Labs is profitable, therefore cash runway is not a concern.
- Decipher Labs is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (82.3%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 13.6x debt.
- Decipher Labs's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 3.5x coverage).
- Decipher Labs's level of debt (10.7%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0.7% vs 10.7% today).
- High level of physical assets or inventory.
management
- The tenure for the Decipher Labs board of directors is about average.
misc
- Decipher Labs is not covered by any analysts.
- Decipher Labs has significant price volatility in the past 3 months.
past
- Decipher Labs has delivered over 20% year on year earnings growth in the past 5 years.
- Decipher Labs used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Decipher Labs has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
- Decipher Labs's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (40.2% vs 22.7%).
- Decipher Labs's 1-year earnings growth is less than its 5-year average (40.2% vs 74.7%)
- Decipher Labs has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- 524752 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524752 is up 10.4% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524752 is up 10.4% outperforming the market in India which returned 8% over the past month.
- Decipher Labs's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Decipher Labs's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Decipher Labs is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Decipher Labs is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Decipher Labs is overvalued based on earnings compared to the India market.
- 524752 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.